Investment Rating - The report does not explicitly state an investment rating for the wearable medical device industry Core Insights - The wearable medical device industry in China has transitioned from consumer-grade functionalities to specialized medical applications, driven by regulatory certifications and clinical data validation, enabling a shift from health monitoring to disease warning and management [3] - The market is expected to grow from CNY 140 billion in 2020 to CNY 230 billion by 2029, with a compound annual growth rate (CAGR) of 7.0% [6] - The industry is evolving towards an integrated health management ecosystem that combines devices, data, and services, focusing on chronic disease management and remote patient monitoring [5][6] Market Background - The wearable medical device market has developed from basic health monitoring to professional medical applications, with a focus on meeting medical device standards and providing clinically accurate data [4][5] - The industry is supported by a framework that includes policy guidance, standardization, technological integration, and clinical validation [3] Market Status - The market size is projected to grow from CNY 1,400.2 billion in 2020 to CNY 1,499.6 billion in 2024, with a CAGR of 1.7% [6] - The market faced a decline in 2022 due to high base effects from previous growth and macroeconomic pressures, but future growth is expected to be driven by policy incentives, technological advancements, and ecosystem integration [6] Market Competition - The competitive landscape is characterized by a mix of specialized medical companies and consumer electronics giants, with companies like Nine安医疗, 乐心医疗, and 乐普医疗 leading in the medical-grade segment [16] - Consumer technology companies such as Huawei and Apple are increasingly entering the medical-grade market, blurring the lines between consumer and medical devices [16] Development Trends - The industry is moving towards "cognitive intelligence," where devices will not only collect data but also analyze and provide decision support in real-time [24] - The application value is evolving from health monitoring to integrated management and deep integration with medical ecosystems, facilitating remote healthcare services [24] - The driving forces are shifting from technological innovation to a dual push from policy and essential healthcare needs, indicating a trend towards becoming a fundamental component of basic healthcare [25]

| 证券代码：300298 | 证券简称：三诺生物 | 公告编号：2025-086 | | --- | --- | --- | | 债券代码：123090 | 债券简称：三诺转债 | | 本次延期换届不会影响公司的正常运营。公司将积极推进董事会换届选举、 监事会改革等工作，并及时履行相应的信息披露义务。 二、部分独立董事任期将届满 根据《上市公司独立董事管理办法》《公司章程》等相关规定，上市公司独 立董事占董事会成员的比例不得低于三分之一，独立董事在上市公司连续任职时 间不得超过六年。公司现任独立董事袁洪先生、康熙雄先生任期将于 2025 年 12 月 22 日届满且连任时间将满 6 年。鉴于目前公司第五届董事会成员共计 7 名， 其中独立董事 3 名，袁洪先生、康熙雄先生的任期届满离任将导致公司独立董事 人数少于董事会成员的三分之一。根据《中华人民共和国公司法》《上市公司独 立董事管理办法》等相关规定，在董事会换届选举工作完成之前，袁洪先生、康 熙雄先生将继续履行其独立董事及相关董事会专门委员会委员职责，直至公司股 东会选举产生新的独立董事。 特此公告！ 三诺生物传感股份有限公司 关于董事会延期换届及部分独 ...

Group 1 - The A-share market indices have shown an upward trend, with the Shanghai Composite Index rising by 0.02%, the Shenzhen Component Index by 0.24%, and the ChiNext Index by 0.64% as of December 4, 2025 [1] - The Medical Device ETF (562600) increased by 0.11%, with the latest price at 0.873 yuan and an intraday turnover rate of 0.58% [1] - Among the constituent stocks, Yirui Technology led with a gain of 3.94%, while Xiangyu Medical experienced the largest decline at 2.78% [1] Group 2 - Long-term demand for medical devices is driven by the relentless pursuit of health and life, indicating that the industry lacks significant cyclicality but may experience short-term fluctuations due to external factors [2] - The medical device industry in China is projected to grow from 1.20 trillion yuan in 2024 to 2.11 trillion yuan by 2030, with an average annual growth rate of 9.85%, driven by aging populations, chronic disease prevalence, and innovations in the industry [2] - By 2026, the industry is expected to see a "moderate recovery" in fundamentals, supported by improving demand, innovation, and policy enhancements, although risks related to demand recovery and cost control policies remain [2]

Investment Rating - The report maintains a "Recommendation" rating for the company, with a target price of 24 yuan and a current price of 17.75 yuan [4][9]. Core Insights - The company reported a revenue of 3.453 billion yuan for the first three quarters of 2025, reflecting an increase of 8.52% year-on-year, while the net profit attributable to the parent company was 211 million yuan, down 17.36% [2][9]. - In Q3 2025, the company achieved a revenue of 1.190 billion yuan, up 13.40% year-on-year, but the net profit dropped significantly by 47.55% to 30 million yuan [2][9]. - The decline in profit is primarily attributed to cross-licensing patent fees impacting short-term profitability, specifically a payment of 19 million USD to Roche, which affected the net profit by approximately 136 million yuan [9]. Financial Performance Summary - The total revenue forecast for 2024A, 2025E, 2026E, and 2027E is 4.443 billion, 4.901 billion, 5.474 billion, and 6.250 billion yuan respectively, with year-on-year growth rates of 9.5%, 10.3%, 11.7%, and 14.2% [4][10]. - The net profit attributable to the parent company is projected to be 326 million, 294 million, 485 million, and 581 million yuan for the same years, with growth rates of 14.7%, -10.1%, 65.3%, and 20.0% respectively [4][10]. - The earnings per share (EPS) is expected to be 0.58, 0.52, 0.87, and 1.04 yuan for 2024A, 2025E, 2026E, and 2027E respectively [4][10]. Market Position and Competitive Landscape - The company is experiencing steady growth in both traditional and continuous glucose monitoring (CGM) businesses, with double-digit revenue growth in Q3 2025 [9]. - The company has successfully navigated patent challenges, reaching a settlement with Roche and obtaining necessary patent licenses, which is crucial for its market expansion [9]. - The report highlights the importance of ongoing innovation and intellectual property management to mitigate risks associated with patent litigation from industry giants [9].

（文章来源：证券日报） 证券日报网讯 12月2日晚间，三诺生物发布公告称，截至2025年11月30日，公司通过股份回购专用证券 账户以集中竞价交易方式累计回购公司股份9，319，800股，占公司当前总股本的比例为1.66%，本次 回购股份的最高成交价为21.39元/股，最低成交价为17.73元/股，成交总金额为184，132，547.34元（不 含交易费用）。 ...

| 证券代码：300298 | 证券简称：三诺生物 | 公告编号：2025-085 | | --- | --- | --- | | 债券代码：123090 | 债券简称：三诺转债 | | 三诺生物传感股份有限公司 关于为控股子公司提供担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 本次提供担保后，公司为被担保人心诺健康提供担保的基本情况如下： 三、被担保人基本情况 1、被担保人基本情况 公司名称：长沙心诺健康产业投资有限公司 成立时间：2015年4月27日 一、担保情况概述 三诺生物传感股份有限公司（以下简称"公司"或者"三诺生物"）于 2025 年 4 月 18 日召开第五届董事会第十七次会议和第五届监事会第十三次会议，于 2025 年 5 月 14 日召开 2024 年年度股东大会，审议并通过《关于为控股子公司 申请综合授信提供担保的议案》，同意公司及合并范围内子公司继续为控股子公 司长沙心诺健康产业投资有限公司（以下简称"心诺健康"）向金融机构申请综 合授信提供担保，担保金额不超过人民币 2 亿元，担保期限自协议生效之日起三 年，在前述担 ...

格隆汇12月2日丨三诺生物(300298.SZ)公布，截至2025年11月30日，公司通过股份回购专用证券账户以 集中竞价交易方式累计回购公司股份9,319,800股，占公司当前总股本的比例为1.66%，本次回购股份的 最高成交价为21.39元/股，最低成交价为17.73元/股，成交总金额为184,132,547.34元（不含交易费 用）。本次回购符合公司既定的回购方案及相关法律法规的要求。 ...

格隆汇12月2日丨三诺生物(300298.SZ)公布，截至2025年11月30日，公司通过股份回购专用证券账户以 集中竞价交易方式累计回购公司股份9,319,800股，占公司当前总股本的比例为1.66%，本次回购股份的 最高成交价为21.39元/股，最低成交价为17.73元/股，成交总金额为184,132,547.34元（不含交易费 用）。本次回购符合公司既定的回购方案及相关法律法规的要求。 ...

| 证券代码：300298 | 证券简称：三诺生物 | 公告编号：2025-084 | | --- | --- | --- | | 债券代码：123090 | 债券简称：三诺转债 | | 三诺生物传感股份有限公司 关于回购公司部分股份的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 三诺生物传感股份有限公司（以下简称"公司"）于 2025 年 2 月 20 日召开 第五届董事会第十六次会议和第五届监事会第十二次会议，审议并通过《关于回 购公司部分股份方案的议案》，同意公司使用自有资金及银行回购专项贷款以集 中竞价交易的方式回购公司部分社会公众股份，用于员工持股计划、股权激励或 者用于转换上市公司发行的可转换为股票的公司债券。回购资金总额不低于人民 币 15,000 万元且不超过人民币 30,000 万元（均含本数），回购价格不超过人民币 34.00 元/股（含），实施期限为自董事会审议通过本次回购部分股份方案之日起 12 个月内。2025 年 6 月 13 日，公司实施完成 2024 年年度权益分派方案，根据 公司《关于回购公司部分股份方案暨取得金融 ...

Group 1 - The 2025 Analyst Conference and the 7th Sina Finance "Golden Unicorn" Best Analyst Awards Ceremony were held in Shanghai, gathering over 300 industry experts to discuss future opportunities in the Chinese capital market [1] - The top honor for the 7th Sina Finance Golden Unicorn Elite Analyst in the innovative drug sector was awarded to the Zheshang Securities research team, led by Chief Analyst Wu Tianhao [1] Group 2 - The strategy for the high-value consumables sector in 2026 indicates optimism due to policy optimization, with expectations for revenue recovery and new product launches [2] - The medical device sector is expected to see performance recovery driven by the resumption of in-hospital bidding and the "Belt and Road" initiative, despite a decline in profit in the first three quarters of 2025 [2] - The home medical sector is anticipated to regain growth, supported by overseas expansion and recovery in revenue and profit growth in 2025 [2] Group 3 - Investment recommendations include high-value consumables companies with cleared procurement risks and new product launches, such as Microelectrophysiology, Aikang Medical, and Weikang Medical [3] - Medical device and home medical companies expected to see steady revenue growth include Mindray Medical, Meihua Medical, and Yuyue Medical, among others [3]